# Phase-2B — Bajaj My Health Care Review-Scaling Replication Checkpoint

Status: **ACTIVE — CROSS-PRODUCT REPLICATION IN PROGRESS**
Date: 2026-08-15

## Purpose

Replicate the Phase-2A governed review-scaling path on a second real Health product and insurer without product-identity-bearing production code.

Product under pressure:

- Insurer: Bajaj General Insurance
- Product: My Health Care Plan (Plan 1)
- Entity: `bajaj_allianz_general:my_health_care`
- Registered source SHA-256: `05dc291324340d5293f9f5f430f44b14e3da34052d6357455714af2dfa499158`

## Generic pipeline execution

The existing generic path was executed without new production code:

`governed registration -> governed registered PDF parse -> currency candidates -> reviewer-ready groups -> MO-029 review-risk routing`

Observed Bajaj results:

- Parsed pages: **53**
- Pages with text: **53**
- Currency candidates: **10**
- Reviewer-ready groups: **10**
- Grouping compression: **0%**
- MO-029 Critical: **2**
- MO-029 High: **5**
- MO-029 Medium: **3**
- MO-029 Low: **0**
- Critical/High groups: **7 / 10 (70%)**
- Adjudication created: **none**
- Publication created: **none**
- Product-identity-bearing production code added for this replication: **0**

## Cross-product comparison with Star Comprehensive

For the comparable real Star Comprehensive currency-review workload after its evidence-backed generic scope improvement:

- Reviewer-ready groups: **12**
- Critical: **0**
- High: **6**
- Medium: **6**
- Critical/High groups: **6 / 12 (50%)**

Bajaj therefore demonstrates that the same generic pipeline generalizes across another insurer/product while exposing a different ambiguity profile. The architecture is not assuming every product has the same review-cost distribution.

## Interpretation

This checkpoint strengthens Phase-2A's scaling claim by showing that the same governed review path runs on a second product with zero new product-specific production code.

It does **not** justify changing MO-029 thresholds merely because Bajaj has a higher Critical/High proportion.

The next diagnostic step is narrow: inspect only the Critical and High Bajaj groups and determine whether their risk is caused by:

1. legitimate conflicting role/table/structural ambiguity;
2. a reusable generic evidence-context gap already demonstrated by the product;
3. unsupported semantics that should remain explicit residue.

Any generic production change requires real evidence that the current representation is systematically missing reusable context. No Bajaj-specific branch, product ID, hash, or reasoning may be added.

## Guardrails

- No publication or adjudication follows from review routing.
- No product-specific production reasoning code.
- No weakening of fail-closed review-risk policy.
- Table/column and role ambiguity remain unresolved until evidence supports binding.
- Cross-product review effort is measured honestly; unfavorable workload distributions are not normalized away.
